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Abstract
Mild cognitive impairment (MCI) is often a prodromal stage for Alzheimer’s disease
(AD) development, with those diagnosed with MCI at increased risk for developing AD. The
present study aimed to provide data to support a prodromal stage of MCI via analysis utilizing
the neuropsychological domain of memory, subjective memory impairment (SMI), and the PET
tau biomarker, AV-1451. It was hypothesized that individuals with SMI would differ
significantly from participants without SMI (nSMI) on measures of memory and level of tau
binding in the entorhinal cortices and the hippocampi. It was further hypothesized that
differences in memory would be mediated by level (high/low) of binding in these
neuroanatomical structures. The sample included 127 cognitively normal (CN) participants,
selected from the Alzheimer’s Disease neuroimaging Initiative 3. Participants were cognitively
normal, free from co-morbid disorders such as depression, and included individuals who had
undergone PET imaging at baseline testing. Results found no significant differences between
memory scores for SMI or nSMI participants, nor were there significant differences between
groups on tau standardized uptake value ratios. There were significant main effects for tau level
and location (left/right entorhinal cortices and left/right hippocampi) for the Wechsler Memory
Scale-IV Logical Memory I test, and in the left entorhinal cortex for Logical Memory II. Current
findings support differences in level of AV-1451 tau binding for story memory. The data
provides a baseline for future researchers to utilize the cognitive measure of story memory in
conjunction with tau level to develop a neuropsychological profile for individuals who may
benefit from earlier intervention to slow progression of neurodegenerative decline.

i

DEDICATION
First, I want to be sure to thank my committee members, Dr. Lane and Dr. Rosen, for
their help and support through this process. It’s a long journey filled with many hurdles (some
quite unexpected!), and your mentorships throughout the development of this project won’t be
forgotten. Thank you!
To the friends who have always been by my side, encouraged me, and who had
confidence in me even when I didn’t: this manuscript, forged from years of work (with some
tears and pure stubbornness mixed in), is for each of you. I love you all.
To my husband, Hunter…nothing I could say would be enough, so all I will say is thank
you. Thank you for your endless confidence in me, thank you for your thoughtfulness and
constant understanding, thank you for everything that you are. I’m not sure I will ever know how
I became so lucky, but you mean the world to me and I can’t wait to start this next chapter with
you by my side.
To my mother, the woman who taught me how to be strong and independent. Your
continual belief and support instilled in me the confidence to know I could do anything (and look
what I did!). Thank you for all you gave me growing up; love, trust, and just enough goofiness to
make me interesting.
To Samantha, my amazing big sister. The strength you show every day proves that we
can persevere and grow, no matter what life gives us. They say you can’t pick your sister, but if I
could, I’d pick you every time.
To my father, I know you would be so proud. I think of you every day and miss you more
than words can say.

iv

ACKNOWLEDGEMENTS
Data collection and sharing for this project was funded by the Alzheimer's Disease
Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) andDOD
ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the
National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering,
and through generous contributions from the following: AbbVie, Alzheimer’s Associatiosn;
Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; BristolMyers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli
Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company
Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy
Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development
LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx
Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal
Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian
Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private
sector contributions are facilitated by the Foundation for the National Institutes of Health
(www.fnih.org). The grantee organization is the Northern California Institute for Research and
Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the
University of Southern California. ADNI data are disseminated by the Laboratory for Neuro
Imaging at the University of Southern California.

v

TABLE OF CONTENTS
ABSTRACT..................................................................................................................................... i
DEDICATION ............................................................................................................................... iv
ACKNOWLEDGEMENTS ............................................................................................................ v
TABLE OF CONTENTS ............................................................................................................... vi
CHAPTER I: INTRODUCTION AND LITERATURE SUPPORT .............................................. 1
Background and Problem Statement .................................................................................... 1
Operational Definitions ........................................................................................................ 1
Biomarkers of Neurodegeneration in MCI and AD ............................................................. 2
Neuropsychological Correlates of Neurodegeneration and Tau .......................................... 3
Subjective Memory Impairment .......................................................................................... 5
Purpose of the Study ............................................................................................................ 5
Research Question I ............................................................................................................. 6
Does the presence of SMI in otherwise cognitively normal participants relate
significantly to neuropsychological functioning?......................................................... 6
Hypotheses for Research Question I .................................................................................... 6
Executive functioning composite scores ...................................................................... 6
Trailmaking Test A ....................................................................................................... 6
Trailmaking Test B ....................................................................................................... 6
Clock drawing test ........................................................................................................ 6
Category fluency test .................................................................................................... 6
Memory composite scores ............................................................................................ 6
Rey Auditory Verbal Learning Test immediate recall ................................................. 7
Rey Auditory Verbal Learning Test delayed recall ...................................................... 7
Wechsler Memory Scale-Fourth Edition Logical Memory I........................................ 7
Wechsler Memory Scale-Fourth Edition Logical Memory II ...................................... 7
Research Question II ............................................................................................................ 7
Does tau binding of AV-1451 in the left and right entorhinal cortices and the left and
right hippocampi differ between participants with SMI and without SMI? ................. 7
Hypotheses for Research Question II .................................................................................. 7
Left entorhinal cortex AV-1451 binding ...................................................................... 7
Right entorhinal cortex AV-1451 binding .................................................................... 7

vi

Left hippocampus AV-1451 binding ............................................................................ 8
Right hippocampus AV-1451 binding.......................................................................... 8
Research Question III .......................................................................................................... 8
Is there an interaction between AV-1451 tau binding and neuropsychologicallymeasured memory functioning, as mediated by SMI? ................................................. 8
Hypotheses for Research Question III ................................................................................. 8
Left entorhinal cortex tau level and memory composite score ..................................... 8
Right entorhinal cortex tau level and memory composite score .................................. 8
Left hippocampus tau level and memory composite score........................................... 8
Right hippocampus tau level and memory composite score ........................................ 8
Left entorhinal cortex tau level and RAVLT immediate recall score .......................... 9
Right entorhinal cortex tau level and RAVLT immediate recall score ........................ 9
Left hippocampus tau level and RAVLT immediate recall score ................................ 9
Right hippocampus tau level and RAVLT immediate recall score .............................. 9
Left entorhinal cortex tau level and RAVLT delayed recall score ............................... 9
Right entorhinal cortex tau level and RAVLT delayed recall score............................. 9
Left hippocampus tau level and RAVLT delayed recall score ..................................... 9
Right hippocampus tau level and RAVLT delayed recall score ................................ 10
Left entorhinal cortex tau level and WMS-IV Logical Memory I score .................... 10
Right entorhinal cortex tau level and WMS-IV Logical Memory I score .................. 10
Left hippocampus tau level and WMS-IV Logical Memory I score .......................... 10
Right hippocampus tau level and WMS-IV Logical Memory I score ........................ 10
Left entorhinal cortex tau level and WMS-IV Logical Memory II score ................... 10
Right entorhinal cortex tau level and WMS-IV Logical Memory II score ................ 11
Left hippocampus tau level and WMS-IV Logical Memory II score......................... 11
Right hippocampus tau level and WMS-IV Logical Memory II score ...................... 11
CHAPTER II: METHODS ........................................................................................................... 12
Participant Characteristics ................................................................................................. 12
Diagnostic Determination .................................................................................................. 13
Cognitive Impairment Status ............................................................................................. 17
Neuropsychological Assessment ....................................................................................... 17
Executive functioning composite ............................................................................... 17

vii

Trail Making Test A & B. .......................................................................................... 17
Category/semantic fluency. ........................................................................................ 18
Clock drawing............................................................................................................. 18
Episodic memory composite ...................................................................................... 18
Rey Auditory Verbal Learning Test. .......................................................................... 19
Wechsler Memory Scale Logical Memory Fourth Edition. ....................................... 19
Biomarker Protocol ............................................................................................................ 20
Statistical Analyses ............................................................................................................ 20
Research Question I ........................................................................................................... 21
Analyses for Research Question I ...................................................................................... 21
Executive functioning composite scores .................................................................... 21
Trail Making Test A ................................................................................................... 21
Trail Making Test B ................................................................................................... 21
Clock drawing test ...................................................................................................... 21
Category fluency test .................................................................................................. 22
Memory composite scores .......................................................................................... 22
Rey Auditory Verbal Learning Test immediate recall ............................................... 22
Rey Auditory Verbal Learning Test delayed recall .................................................... 22
Wechsler Memory Scale-Fourth Edition Logical Memory I...................................... 22
Wechsler Memory Scale-Fourth Edition Logical Memory II .................................... 23
Research Question II .......................................................................................................... 23
Analyses for Research Question II .................................................................................... 23
Left entorhinal cortex AV-1451 binding .................................................................... 23
Right entorhinal cortex AV-1451 binding .................................................................. 23
Left hippocampus AV-1451 binding .......................................................................... 23
Right hippocampus AV-1451 binding........................................................................ 24
Research Question III ........................................................................................................ 24
Analyses for Research Question III ................................................................................... 24
Left entorhinal cortex tau level and memory composite score ................................... 24
Right entorhinal cortex tau level and memory composite score ................................ 24
Left hippocampus tau level and memory composite score......................................... 24

viii

Right hippocampus tau level and memory composite score ...................................... 25
Left entorhinal cortex tau level and RAVLT immediate recall score ........................ 25
Right entorhinal cortex tau level and RAVLT immediate recall score ...................... 25
Left hippocampus tau level and RAVLT immediate recall score .............................. 25
Right hippocampus tau level and RAVLT immediate recall score ............................ 25
Left entorhinal cortex tau level and RAVLT delayed recall score ............................. 26
Right entorhinal cortex tau level and RAVLT delayed recall score........................... 26
Left hippocampus tau level and RAVLT delayed recall score ................................... 26
Right hippocampus tau level and RAVLT delayed recall score ................................ 26
Left entorhinal cortex tau level and WMS-IV Logical Memory I score .................... 27
Right entorhinal cortex tau level and WMS-IV Logical Memory I score .................. 27
Left hippocampus tau level and WMS-IV Logical Memory I score .......................... 27
Right hippocampus tau level and WMS-IV Logical Memory I score ........................ 27
Left entorhinal cortex tau level and WMS-IV Logical Memory II score ................... 27
Right entorhinal cortex tau level and WMS-IV Logical Memory II score ................ 28
Left hippocampus tau level and WMS-IV Logical Memory II score......................... 28
Right hippocampus tau level and WMS-IV Logical Memory II score ...................... 28
CHAPTER III: RESULTS ............................................................................................................ 31
Assumptions....................................................................................................................... 31
EF Composite. ............................................................................................................ 32
Trail Making A. .......................................................................................................... 34
Trail Making B. .......................................................................................................... 35
Clock........................................................................................................................... 37
Category Fluency Test. ............................................................................................... 38
Memory Composite. ................................................................................................... 39
RAVLT Immediate Recall.......................................................................................... 41
RAVLT Delay Recall. ................................................................................................ 43
LM Immediate Recall. ................................................................................................ 45
LM Delay Recall. ....................................................................................................... 47
Participant Characteristics. ......................................................................................... 48
Analyses by research question ........................................................................................... 48

ix

Research Question I: Subjective Memory Impairment and Cognitive Measures ...... 48
Research Question II: Subjective Memory Complaint and Biomarker Level ................... 55
Research Question III: Subjective Memory Impairment, Tau Level, and Memory
Measures ............................................................................................................................ 57
CHAPTER IV: DISCUSSION ..................................................................................................... 74
Findings.............................................................................................................................. 74
Executive functioning in SMI and nSMI groups. ....................................................... 75
Memory in SMI and nSMI groups. ............................................................................ 76
Tau binding of AV-1451 in the entorhinal cortices and hippocampi. ........................ 77
Neuropsychological functioning and SMI, by level of tau AV-1451 binding ........... 78
Strengths ............................................................................................................................ 79
Limitations ......................................................................................................................... 80
Future directions and recommendations ............................................................................ 81
References .......................................................................................................................... 84

x

4

1
CHAPTER I: INTRODUCTION AND LITERATURE SUPPORT
Background and Problem Statement
Mild cognitive impairment (MCI) is often a prodromal stage for Alzheimer’s disease
(AD) development, with those diagnosed with MCI at increased risk for developing AD
(Bruscoli & Lovestone, 2004; Petersen et al., 2001). While there is no cure for MCI or AD,
research shows that earlier treatment intervention in patients with neurodegenerative disorders
significantly slows progression (Doody, Geldmacher, Gordon, Perdomo, & Pratt, 2001; Nelson
& Tabet, 2015; Vellas et al., 2011). Therefore, it follows that earlier detection of MCI would
allow for earlier implementation of interventions and/or preventative medication to slow
progression of neurodegeneration.
Recent research on early stages of AD have discovered changes in cognitive domainspecific areas before clinical diagnosis is made (Chen et al., 2001; Hamel et al., 2015).
Specifically, Bäckman, Jones, Berger, Laukka, and Small (2005) completed a meta-analysis of
47 studies with clinically normal and preclinical AD cases to determine which cognitive domains
may be impacted ahead of diagnostically indicated neurocognitive decline. Their results found
significant changes in nearly all cognitive domains (including episodic memory), though with
sparing of primary memory, prior to AD diagnosis (per Bäckman et al., “primary memory”
referred to the Digit Span–Forward subtest from the WAIS–R and the primary memory score
from the lag method (Tulving & Colotla, 1970). The authors concluded that future research
should incorporate their findings with biological data to help further understanding of the
diagnostic utility of these preclinical domains.
Operational Definitions
Diagnosis of MCI (Petersen, 2004) requires a decline in neurocognitive function from a
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premorbid level that does not negatively impact the ability of the person to complete activities of
daily living (American Psychiatric Association, 2013).
Neurodegeneration in the form of AD is marked by memory impairment and cognitive
decline which impairs daily functioning (American Psychiatric Association, 2013). This is a
deteriorative disorder with no known cure. Additionally, those with AD tend to have higher
levels of tau and decreased levels of β-amyloid peptide (Aβ42; Lee, Goedert, & Trojanowski,
2001; Murphy & LeVine, 2010).
There are myriad methods for defining subjective memory impairment (SMI), with many
researchers using a variation of single self-report yes/no scaled questions (Abdulrab & Heun,
2008). While there is no consensus on defining SMI for clinical or research purposes, this study
will define SMI as an awareness of memory deficits in the patient as indicated by a “yes”
response on question 10 of the Geriatric Depression Scale (“Do you feel you have more
problems with memory than most?”).
Biomarkers of Neurodegeneration in MCI and AD
Biomarkers for tau tangles were originally assessed post mortem and broken in to stages
per Braak & Braak (1991) criteria. Tau accumulation in Braak stages I and II relate to NFTs in
the transentorhinal cortex within the left temporal lobe (Braak & Braak, 1995). Stages I and II
relate to non-clinical presentations and are considered “prodromal” stages; that is, when some tau
accumulation occurs, without clinical symptomatology. Stages III-IV involve the limbic system
and identify incipient Alzheimer's disease. The neocortical stages (V-VI) classify fully developed
Alzheimer's disease. Historically, Braak staging was determined via examination of sections of
brain obtained after death, and thus implementation of staging during the disease’s progression
was impossible. However, recently neuroimaging has allowed clinicians to apply Braak staging
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via biomarkers assessed through imaging techniques such as positron emission tomography
(PET) to provide a realistic and applicable means to asses for pathology of MCI and AD
development in vivo (Braak, Alafuzoff, Arzberger, Kretzschmar, & Del Tredici, 2006).
Tau biomarkers have been found to correlate well with decreases in functioning (Buckley
et al., 2017; Vogel et al., 2017) and are a key focus of current neurodegenerative research. Tau is
a protein within brain cells which assists in transportation of other proteins within neurons
(Mandelkow & Mandelkow, 1994). Neurofibrillary tangles (NFT) are an intracellular
accumulation of twisted tau protein fragments, resulting in poor or no transmission within
microtubules, eventually leading to cell death. Simply, accumulation of tau tangles leads to death
of brain cells and impaired functioning, and NFTs are a characteristic structural abnormality
found in the brains of patients with AD (Dickson, 2004). Amyloid plaques are another common
finding in patients with AD, which develops extracellularly, but is not normally produced outside
of neurodegenerative processes (Murphy, & LeVine, 2010). However, biomarkers for tau have
been shown to be more pathological for MCI versus cognitively normal (CN) patients (Eliassen
et al., 2017). Specifically, tau is a stronger correlate of cognitive function than amyloid.
Additionally, NFTs relate to normal aging and AD pathology, and binding of tau biomarkers are
utilized in imaging assessment of neurodegeneration (Maass et al., 2017).
Neuropsychological Correlates of Neurodegeneration and Tau
Specific neuropsychological domains have been found to be more strongly correlated
with impaired functioning and age progression. Specifically, episodic memory has shown myriad
studies supporting deficits related to decline which is outside of the realm of normal aging
(Ricci, Graef, Blundo, & Miller, 2012). Verbal and semantic fluency are widely used to assess
for cognitive decline in older adults (Henry, Crawford, & Phillips, 2004), while executive
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functioning is a hallmark measure of neuropsychological decline in older adults (Kirova, Bays,
& Lagalwar, 2015), both within normal aging and patients with neurodegenerative disorders.
A recent study by Digma, Madsen, Reas, Dale, Brewer, and Banks (2019) utilized 131
amyloid-positive participants who underwent flortaucipir (FTP) PET, MRI, and
neuropsychological testing to determine relationships between tau deposition and cognitive
impairment. Their results found cognitive domains which correlated with tau deposition.
Notably, they found a relationship between levels of tau via FTP and the cognitive domains of
language fluency and aspects of visuospatial functioning; specifically, as performances on these
tasks declined, the level of tau in various brain regions increased. The concluded that worse
cognition was related to increased tau presence and cortical thinning in their patients.
Additionally, Eckerström et al. (2013) found a specific memory task (Rey Auditory Verbal
Learning test) in conjunction with level of tau accumulation was the strongest predictor of
conversion to dementia.
Thus, it is clear neuropsychological assessment is widely used to detect cognitive deficits
and monitor decline in the aging population. Neuropsychological functioning has repeatedly
been shown to accurately assess cognitive functioning and decline (Lezak, Howieson, Bigler, &
Tranel, 2012). Specifically, individual performance on neuropsychological assessments of
cognitive domains (memory, attention, language, executive functioning, visuospatial, and motor
functioning) have repeatedly and consistently supported a direct relationship to functioning of
each domain. Consequently, use of neuropsychological tools in assessing and monitoring MCI
and AD development is not only beneficial, but crucial. Research has found a relationship
between neuropsychological data and biomarkers (Engelborghs et al., 2006), though few have
looked at the specific AV-1451 biomarker and neuropsychological functioning. Thus, one of the
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aims of the current research focused on level of tau accumulation in the brain, and the impact it
had on neuropsychological assessment of cognitive functioning.
Subjective Memory Impairment
The presence of SMI has been shown to be a possible early sign of MCI or AD
development (Jessen et al., 2010), though limited research has been conducted which provides
enough support for SMI presence alone to indicate need for a preventative medication regime in
patients. Research shows individuals with normal neuropsychological functioning but with SMI
show brain-based deficits in gray matter as compared to cognitively intact adults (Saykin et al.,
2006). Additionally, SMI within MCI populations relates to impaired neuropsychological
functioning, specifically verbal episodic memory (Gifford et al., 2015). A strong predictor for
transition to MCI is the presence of SMI (Reisberg & Gauthier, 2008), with various studies
supporting MCI as a prodromal stage of AD (Geerlings, Jonker, Bouter, Ader, & Schmand,
1999). Thus, recognition and understanding of the relationship between SMI and
neuropsychological functioning, prior to development of MCI or AD (i.e. individuals with SMI
only), can provide clinical and diagnostic information which may allow for earlier interventions,
and result in slowed degeneration for individuals likely to develop MCI and AD.
Purpose of the Study
The current study focused on biomarker 18F-AV-1451 [(F-18)T807] (AV-1451) and its
relationship to neuropsychological performances and subjective memory impairment. Biomarker
AV-1451 via PET imaging has increased binding in MCI and AD patients (Cho et al., 2016), and
binds to AD-specific tau throughout the brain (Das et al., 2018), with increased binding in the
medial temporal lobe (Vemuri et al., 2017). Research looking at tau biomarkers in AD patients
discovered AV-1451 as a biomarker of disease staging in AD, with increased binding found with
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advanced stages of the disease (Mattsson et al., 2017). The current study’s purpose is to assist in
earlier detection of cognitive decline, through utilization of SMI (“Do you feel you have more
problems with your memory than others?), neuropsychological assessment, and level of AV1451 tau biomarker via PET imaging.
Research Question I
Does the presence of SMI in otherwise cognitively normal participants relate
significantly to neuropsychological functioning?
Hypotheses for Research Question I
Executive functioning composite scores. There will not be a significant difference
between SMI and no SMI (nSMI) participants on an executive functioning (EF) composite score.
Trailmaking Test A. There will not be a significant difference between SMI and nSMI
participants on Trail Making Test A scores.
Trailmaking Test B. There will not be a significant difference between SMI and nSMI
participants on Trail Making Test B scores.
Clock drawing test. There will not be a significant difference between SMI and nSMI
participants on clock drawing scores.
Category fluency test. There will not be a significant difference between SMI and nSMI
participants on category fluency scores.
Memory composite scores. There will be a significant difference between SMI and
nSMI participants on a memory composite score.
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Rey Auditory Verbal Learning Test immediate recall. There will be a significant
difference between SMI and nSMI participants in episodic memory, as measured by the Rey
Auditory Verbal Learning test (RAVLT) immediate recall.
Rey Auditory Verbal Learning Test delayed recall. There will be a significant
difference between SMI and nSMI participants in episodic memory, as measured by the Rey
Auditory Verbal Learning test (RAVLT) delayed recall.
Wechsler Memory Scale-Fourth Edition Logical Memory I. There will be a
significant difference between SMI and nSMI participants in episodic memory, as measured by
the Wechsler Memory Scale-Fourth Edition (WMS-IV) Logical Memory I.
Wechsler Memory Scale-Fourth Edition Logical Memory II. There will be a
significant difference between SMI and nSMI participants in episodic memory, as measured by
the WMS-IV Logical Memory II.
Research Question II
Does tau binding of AV-1451 in the left and right entorhinal cortices and the left and
right hippocampi differ between participants with SMI and without SMI?
Hypotheses for Research Question II
Left entorhinal cortex AV-1451 binding. Participants with SMI will have increased
binding of AV-1451 tau in the left entorhinal cortex.
Right entorhinal cortex AV-1451 binding. Participants with SMI will have increased
binding of AV-1451 tau in the right entorhinal cortex.
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Left hippocampus AV-1451 binding. Participants with SMI will have increased binding
of AV-1451 tau in the left hippocampus.
Right hippocampus AV-1451 binding. Participants with SMI will have increased
binding of AV-1451 tau in the left hippocampus.
Research Question III
Is there an interaction between AV-1451 tau binding and neuropsychologically-measured
memory functioning, as mediated by SMI?
Hypotheses for Research Question III
Left entorhinal cortex tau level and memory composite score. When grouped by level
(high/low) of AV-1451 binding in the left entorhinal cortex, there will be significant differences
between SMI and nSMI participants on memory composite scores.
Right entorhinal cortex tau level and memory composite score. When grouped by
level (high/low) of AV-1451 binding in the right entorhinal cortex, there will be significant
differences between SMI and nSMI participants on memory composite scores.
Left hippocampus tau level and memory composite score. When grouped by level
(high/low) of AV-1451 binding in the left hippocampus, there will be significant differences
between SMI and nSMI participants on memory composite scores.
Right hippocampus tau level and memory composite score. When grouped by level
(high/low) of AV-1451 binding in the right hippocampus, there will be significant differences
between SMI and nSMI participants on memory composite scores.
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Left entorhinal cortex tau level and RAVLT immediate recall score. When grouped
by level (high/low) of AV-1451 binding in the left entorhinal cortex, there will be significant
differences between SMI and nSMI participants on RAVLT immediate recall scores.
Right entorhinal cortex tau level and RAVLT immediate recall score. When grouped
by level (high/low) of AV-1451 binding in the right entorhinal cortex, there will be significant
differences between SMI and nSMI participants on RAVLT immediate recall scores.
Left hippocampus tau level and RAVLT immediate recall score. When grouped by
level (high/low) of AV-1451 binding in the left hippocampus, there will be significant
differences between SMI and nSMI participants on RAVLT immediate recall scores.
Right hippocampus tau level and RAVLT immediate recall score. When grouped by
level (high/low) of AV-1451 binding in the right hippocampus, there will be significant
differences between SMI and nSMI participants on RAVLT immediate recall scores.
Left entorhinal cortex tau level and RAVLT delayed recall score. When grouped by
level (high/low) of AV-1451 binding in the left entorhinal cortex, there will be significant
differences between SMI and nSMI participants on RAVLT delayed recall scores.
Right entorhinal cortex tau level and RAVLT delayed recall score. When grouped by
level (high/low) of AV-1451 binding in the right entorhinal cortex, there will be significant
differences between SMI and nSMI participants on RAVLT delayed recall scores.
Left hippocampus tau level and RAVLT delayed recall score. When grouped by level
(high/low) of AV-1451 binding in the left hippocampus, there will be significant differences
between SMI and nSMI participants on RAVLT delayed recall scores.
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Right hippocampus tau level and RAVLT delayed recall score. When grouped by
level (high/low) of AV-1451 binding in the right hippocampus, there will be significant
differences between SMI and nSMI participants on RAVLT delayed recall scores.
Left entorhinal cortex tau level and WMS-IV Logical Memory I score. When
grouped by level (high/low) of AV-1451 binding in the left entorhinal cortex, there will be
significant differences between SMI and nSMI participants on WMS-IV Logical Memory I
scores.
Right entorhinal cortex tau level and WMS-IV Logical Memory I score. When
grouped by level (high/low) of AV-1451 binding in the right entorhinal cortex, there will be
significant differences between SMI and nSMI participants on WMS-IV Logical Memory I
scores.
Left hippocampus tau level and WMS-IV Logical Memory I score. When grouped by
level (high/low) of AV-1451 binding in the left hippocampus, there will be significant
differences between SMI and nSMI participants on WMS-IV Logical Memory I scores.
Right hippocampus tau level and WMS-IV Logical Memory I score. When grouped
by level (high/low) of AV-1451 binding in the right hippocampus, there will be significant
differences between SMI and nSMI participants on WMS-IV Logical Memory I scores.
Left entorhinal cortex tau level and WMS-IV Logical Memory II score. When
grouped by level (high/low) of AV-1451 binding in the left entorhinal cortex, there will be
significant differences between SMI and nSMI participants on WMS-IV Logical Memory II
scores.
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Right entorhinal cortex tau level and WMS-IV Logical Memory II score. When
grouped by level (high/low) of AV-1451 binding in the right entorhinal cortex, there will be
significant differences between SMI and nSMI participants on WMS-IV Logical Memory II
scores.
Left hippocampus tau level and WMS-IV Logical Memory II score. When grouped
by level (high/low) of AV-1451 binding in the left hippocampus, there will be significant
differences between SMI and nSMI participants on WMS-IV Logical Memory II scores.
Right hippocampus tau level and WMS-IV Logical Memory II score. When grouped
by level (high/low) of AV-1451 binding in the right hippocampus, there will be significant
differences between SMI and nSMI participants on WMS-IV Logical Memory II scores.
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CHAPTER II: METHODS
Participant Characteristics
Data used in the preparation of this article were obtained from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). The ADNI was launched in 2003
as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The
primary goal of ADNI has been to test whether serial magnetic resonance imaging (MRI),
positron emission tomography (PET), other biological markers, and clinical and
neuropsychological assessment can be combined to measure the progression of MCI ad AD. For
up-to-date information, see www.adni-info.org.
Participants for the current study were pulled from the Alzheimer’s Disease
Neuroimaging Initiative-3 study (ADNI3; http://adni.loni.usc.edu/), created in 2016 to track
progression of neurodegeneration. The ADNI3 study is a continuation of the original ADNI
database which was created in 2004 for the purpose of earlier detection of AD, with the goal to
utilize this information to support earlier intervention, prevention, and treatment of the disease.
ADNI3 continues to focus on earlier detection of AD, through the addition of utilization of tau
PET and functional imaging techniques, which were not included in the original ADNI studies.
The ADNI3 study collects and utilizes data from various locations in the United States pertaining
to cognitive impairment and AD, with the aim of better understanding its course and
development. Participates in ADNI3 include males and females aged 55 to 90, across CN, MCI,
and mild AD groups. Exclusion criteria for ADNI participants included any significant
neurologic disease (i.e. Parkinson’s, Huntington’s, normal pressure hydrocephalus, brain tumor,
progressive supranuclear palsy), contraindications for MRI and PET imaging (i.e. pacemaker,
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metal fragments), and certain co-morbid diagnoses (i.e., schizophrenia, substance abuse, unstable
medical conditions). For a full list of inclusion and exclusion criteria, and for up to date
information, please visit the ADNI website (www.adni-info.org).
Diagnostic Determination
The criteria of CN, as defined by ADNI and subsequently utilized in this study, included
participants (a) with or without SMI verified by a study partner, (b) with normal memory
function as indicated by score cutoffs on the Logical Memory II subscale of the Wechsler
Memory Scale-Revised (WMS-R), based on level of education, (c) with Mini-Mental Status
Examination (MMSE) score between 24 and 30, (d) with Clinical Dementia Rating (CDR) score
of 0, (e) with absence of significant impairment in cognitive functions or activities of daily
living, and (f) with stability of medications for at least 4 weeks. For the purposes of the current
study, anyone who obtained a score of 10 or higher on the Geriatric Depression Scale, indicating
clinical levels of depression, were excluded.
The current study included participants characterized by ADNI3 as CN, who completed a
neuropsychological battery, the Geriatric Depression Scale (GDS), PET imaging, and
apolipoprotein-ɛ4 (APOE) collection at a baseline study visit. One participant had a score of 10
on the GDS indicating mild depression and was excluded from the study. APOE results were
unavailable for two participants (both without SMI) and were therefore excluded. The final
sample size consisted of 127 individuals (see Table 1 for demographic breakdown). All study
procedures were approved by National Louis University’s Institutional Review Board prior to
data access or analysis of data.
The current sample included 127 participants without MCI or dementia (i.e. CN).
Participants in this group were an average of 79 years of age (50% female) with 17 years of
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education.
Of the 127 participants, 20 individuals were classified as SMI. The SMI participants were
an average age of 76 years of age (65%) females with 17 years of education. The remaining 107
individuals were classified as nSMI group and had an average age of 79 years (48% female) and
an average of 17 years of education (see Table 1).

15
Table 1.
Demographic and Clinical Characteristics of Study Group
Total (N = 127)

SMI Group (n = 20)

nSMI Group (n = 107)

p-value

Mean Age (SD), in years

79 (7)

76 (6)

79 (7)

.08

Mean Education (SD), in years

17 (2)

17 (2)

17 (3)

.71

64 (50.4%)

13 (65.0%)

51 (47.7%)

.24

Sex (%)
Female
Race/Ethnicity (%)
American Indian
African American
Asian, Pacific Islander
Caucasian
More than One Race
APOE- ɛ4, % positive
Notes. SD = standard deviation.

1 (.8%)
5 (3.9%)
2 (1.6%)
117 (92.1%)
2 (1.6%)
30

1 (5.0%)
19 (95.0%)
40

1 (.9%)
4 (3.7%)
2 (1.9%)
98 (91.6%)
2 (1.9%)
28

.09

.32
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Cognitive Impairment Status
The current study defined SMI as a complaint of memory difficulties, as indicated by a
“yes” response on question 10 of the Geriatric Depression Scale (“Do you feel you have more
problems with memory than most?”). Thus, participants with a “yes” response to this question
were separated into the SMI group, while those with a “no” response were categorized as nSMI.
Neuropsychological Assessment
All participants completed a neuropsychological battery at baseline, which included the
following measures/domains utilized in the current study:
Executive functioning composite. Composite executive functioning (EF) scores were
created previously by Gibbons et al. (2012) and utilized in the current study. Specifically, this
composite score included total scores from the WAIS-R Digit Symbol Substitution, Digit Span
Backwards, Trails A and B, Category Fluency, and Clock Drawing to create an overall
composite score for EF. The EF Composite score was standardized to a z-score with a mean of
zero and an SD of one. Thus, when interpreting, higher scores indicate better functioning, and
lower EF composite scores indicate below average functioning. The range of EF composite
scores fall along the same continuum as z-scores.
Trail Making Test A & B. The Trail Making Test was originally constructed in 1938
and consists of two separate tasks (Strauss, Sherman, & Spreen, 2006). Task A requires
individuals to draw lines with a pencil to sequentially connect 25 encircled numbers which are
randomly arranged on a page. Task B requires individuals to connect, by making pencil lines, 25
encircled numbers and letters sequentially by alternating numbers and letters. Each participant
was instructed to complete a practice set before beginning the experimental set. Both tasks
require attention, visual scanning, visuo-spatial memory, and working memory for the target
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sequence. Task B requires increased working memory to keep two target sequences ready and
reflects cognitive flexibility and the ability to maintain sets (Quinones et al., 2009). The Trail
Making Test A (TMT A) and B (TMT B) have been shown to be significant predictors of decline
from MCI to AD in conjunction with MRI and CSF biomarkers (Ewers et al., 2012). Scores are
described and compared in seconds taken to complete the task, with higher scores (time)
indicating worse performance.
Category/semantic fluency. The category fluency task requires the participant to
produce as many words as possible from a specific category provided by the examiner (Strauss et
al., 2006). Each task produced a raw score based on raw number of words was produced by the
participant in an allot amount of time. These raw scores were then converted to a standard score
based on gender, age, and education. Category fluency, specifically animal naming, is widely
used to asses for cognitive deficits in older adults (Henry et al., 2004).
Clock drawing. Clock drawing is a measure of visuospatial, constructional, and
executive function and is used as a clinical screener for dementia and executive dysfunction
(Strauss et al., 2006). The clock drawing test is used as a clinical screener for dementia and
executive dysfunction (Strauss et al., 2006). Scores on the clock drawing test utilize raw scores
and range from 0 to 5, with higher scores indicating better performance (accurate placement and
inclusion of all numbers, and accurate setting of the clock hands to a specific time).
Episodic memory composite. A composite memory score was created by Crane et al.
(2012) within the ADNI database and includes the Rey Auditory Verbal Learning test (RAVLT;
2 versions), AD Assessment Schedule – Cognition (ADAS-Cog), Mini-Mental State
Examination (MMSE), and the Wechsler Memory Scale - Fourth Edition (WMS-IV) Logical
Memory I and II tests. The memory composite score was used as a measure of overall memory.
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As above, the memory composite score was standardized to a z-score with a mean of zero and an
SD of one. Thus, when interpreting, higher scores indicate better functioning, and lower memory
composite scores indicate below average functioning. The range of memory composite scores
fall along the same continuum as z-scores.
Rey Auditory Verbal Learning Test. The Rey Auditory Verbal Learning Test
(RAVLT) is widely used in assessing different forms of dementia (Ricci et al., 2012), providing
support for utility of RAVLT as a measure of memory via auditory list learning. RAVLT
performances are based on raw scores, utilizing the total number of words recalled by the
participant for each trial. A higher number related to better performance.
Wechsler Memory Scale Logical Memory Fourth Edition. The Wechsler Memory
Scale- Fourth Edition (WMS-IV; Wechsler, 2009) is a series of memory tests designed to assess
a participant’s auditory, verbal, visual, and working memory, and includes an “older adult”
version for those over the age of 69. Within the WMS-IV, participants were administered
Logical Memory I & II in which participants were required to listen to two short stories read by
the examiner and then recall the narratives after a 20 - 30 min delay. WMS-IV Logical Memory I
and II assess contextual verbal memory and have been found to be a strong tool for accurately
assessing memory impairment (Lezak et al., 2012), and has shown specificity for episodic
memory deficits (Rabin et al., 2009). Scoring for both WMS-IV Logical Memory tests was based
on raw number of details recalled on two stories in combination across immediate and delayed
trials. Higher scores across either Logical Memory I or Logical Memory II indicated better
performance.
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Biomarker Protocol
Research conducted by Mishra et al. (2017) provides support for use of a partial-volume
corrected tau-PET standardized uptake value ratios (SUVR) cut-off of 1.25 to separate CN adults
into low and high tau groups. Mishra et al., 2017 used a bootstrapped sparse k-means analysis to
determine the 1.25 SUVR cut off. The medial temporal region has been found to be the brain
area most heavily impacted by tau accumulation after correcting for z-scores specific to each
region of interest in their study (Vemuri et al., 2017).
Verbal and visual memory have been found to be positively correlated with tau binding in
the medial temporal regions (Cho et al., 2016). Specifically, poorer performance on tasks of
verbal delayed recall from the MMSE related to higher accumulation of tau in the lateral and
medial temporal and posterior cingulate cortices. As well, visual delayed recall on the RCFT
related to higher levels of tau accumulation in lateral and medial temporal and posterior cingulate
cortices for older adults with MCI and AD (Cho et al., 2016).
Thus, the current study utilized the cut off 1.25 for SUVR raw scores as per Mishra et al.,
2017 to categorize participants into low (≤1.2499) and high (≥1.2500) tau groups, based on tau
accumulation in the medial temporal lobes. Specifically, the right and left entorhinal cortices, as
well as the left and right hippocampi, were assessed as regions of interest in how tau
accumulation in these regions relates to cognitive functioning.
Statistical Analyses
Prior to all analyses, demographic data was compared to assess for any differences in
groups for the following factors: age, gender, ethnicity, education level, and APOE ɛ4 status
(status: positive = ɛ2/ ɛ4, ɛ3/ ɛ4, ɛ4/ ɛ4; negative = ɛ2/ ɛ2, ɛ2/ ɛ3, ɛ3/ ɛ3). Each of these variables
(age, gender, ethnicity, education level, and APOE ɛ4 status) were included in subsequent
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analyses to control for possible confounding factors and individual differences. Specifically, a
chi-square test for independence was run to assess differences between SMI and nSMI for
gender, ethnicity, and APOE ɛ4 status. An independent samples t-test was run to determine any
differences between SMI and nSMI for age and education.
Research Question I
Does the presence of SMI in otherwise cognitively normal patients relate significantly to
neuropsychological functioning?
Analyses for Research Question I
Executive functioning composite scores. A one-way Analysis of Covariance
(ANCOVA) was run, with SMI and nSMI as categorical independent variables and EF
composite score as the dependent variable. Gender, age, ethnicity, education, and APOE status
were used as covariates to control for individual differences.
Trail Making Test A. A one-way ANCOVA was run with SMI and nSMI as categorical
independent variables and Trails A score as the dependent variable. Gender, age, ethnicity,
education, and APOE status were used as covariates to control for possible individual
differences.
Trail Making Test B. A one-way ANCOVA was run with SMI and nSMI as categorical
independent variables and Trails B score as the dependent variable. Gender, age, ethnicity,
education, and APOE status were used as covariates to control for individual differences.
Clock drawing test. A one-way ANCOVA was run with SMI and nSMI as categorical
independent variables and clock drawing score as the dependent variable. Gender, age, ethnicity,
education, and APOE status were used as covariates to control for individual differences.
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Category fluency test. A one-way ANCOVA was run with SMI and nSMI as categorical
independent variables and category fluency score as the dependent variable. Gender, age,
ethnicity, education, and APOE status were used as covariates to control for individual
differences.
Memory composite scores. A one-way ANCOVA was run, with SMI and nSMI as
categorical independent variables and memory composite score as the dependent variable.
Gender, age, ethnicity, education, and APOE status were used as covariates to control for
individual differences.
Rey Auditory Verbal Learning Test immediate recall. A one-way ANCOVA was run
with SMI and nSMI as categorical independent variables and RAVLT immediate recall score as
the dependent variable. Gender, age, ethnicity, education, and APOE status were used as
covariates to control for individual differences.
Rey Auditory Verbal Learning Test delayed recall. A one-way ANCOVA was run
with SMI and nSMI as categorical independent variables and RAVLT delayed recall score as the
dependent variable. Gender, age, ethnicity, education, and APOE status were used as covariates
to control for individual differences.
Wechsler Memory Scale-Fourth Edition Logical Memory I. A one-way ANCOVA
was run with SMI and nSMI as categorical independent variables and WMS-IV Logical Memory
I score as the dependent variable. Gender, age, ethnicity, education, and APOE status were used
as covariates to control for individual differences.
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Wechsler Memory Scale-Fourth Edition Logical Memory II. A one-way ANCOVA
was run with SMI and nSMI as categorical independent variables and WMS-IV Logical Memory
II score as the dependent variable. Gender, age, ethnicity, education, and APOE status were used
as covariates to control for individual differences.
Research Question II
Does tau binding of AV-1451 in the left and right entorhinal cortices and the left and right
hippocampi differ between participants with SMI and without SMI?
Analyses for Research Question II
Left entorhinal cortex AV-1451 binding. A one-way ANCOVA was run with SMI and
nSMI as categorical independent variables and left entorhinal tau standardized uptake value
ratios (SUVR) as the dependent variable. Gender, age, ethnicity, education, and APOE status
were used as covariates to control for individual differences.
Right entorhinal cortex AV-1451 binding. A one-way ANCOVA was run with SMI
and nSMI as categorical independent variables and right entorhinal tau SUVR as the dependent
variable. Gender, age, ethnicity, education, and APOE status were used as covariates to control
for individual differences.
Left hippocampus AV-1451 binding. A one-way ANCOVA was run with SMI and
nSMI as categorical independent variables and left hippocampus SUVR as the dependent
variable. Gender, age, ethnicity, education, and APOE status were used as covariates to control
for individual differences.
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Right hippocampus AV-1451 binding. A one-way ANCOVA was run with SMI and
nSMI as categorical independent variables and right hippocampus SUVR as the dependent
variable. Gender, age, ethnicity, education, and APOE status were used as covariates to control
for individual differences.
Research Question III
Is there an interaction between AV-1451 tau binding and neuropsychologically-measured
memory functioning, as mediated by SMI?
Analyses for Research Question III
Left entorhinal cortex tau level and memory composite score. A two-way ANCOVA
was run, with tau level in the left entorhinal cortex and SMI group as independent variables, and
memory composite as the dependent variable. Gender, age, ethnicity, education, and APOE
status were used as covariates to control for individual differences.
Right entorhinal cortex tau level and memory composite score. A two-way ANCOVA
was conducted, with tau level in the right entorhinal cortex and SMI group as independent
variables, and memory composite as the dependent variable. Gender, age, ethnicity, education,
and APOE status were used as covariates to control for individual differences.
Left hippocampus tau level and memory composite score. A two-way ANCOVA was
conducted, with tau level in the left hippocampus and SMI group as independent variables, and
memory composite as the dependent variable. Gender, age, ethnicity, education, and APOE
status were used as covariates to control for individual differences.
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Right hippocampus tau level and memory composite score. A two-way ANCOVA
was conducted, with tau level in the right hippocampus and SMI group as independent variables,
and memory composite as the dependent variable. Gender, age, ethnicity, education, and APOE
status were used as covariates to control for individual differences.
Left entorhinal cortex tau level and RAVLT immediate recall score. A two-way
ANCOVA was conducted, with tau level in the left entorhinal cortex and SMI group as
independent variables, and RAVLT immediate recall as the dependent variable. Gender, age,
ethnicity, education, and APOE status were used as covariates to control for individual
differences.
Right entorhinal cortex tau level and RAVLT immediate recall score. A two-way
ANCOVA was conducted, with tau level in the right entorhinal cortex and SMI group as
independent variables, and RAVLT immediate recall as the dependent variable. Gender, age,
ethnicity, education, and APOE status were used as covariates to control for individual
differences.
Left hippocampus tau level and RAVLT immediate recall score. A two-way
ANCOVA was conducted, with tau level in the left hippocampus and SMI group as independent
variables, and RAVLT immediate recall as the dependent variable. Gender, age, ethnicity,
education, and APOE status were used as covariates to control for individual differences.
Right hippocampus tau level and RAVLT immediate recall score. A two-way
ANCOVA was conducted, with tau level in the right hippocampus and SMI group as
independent variables, and RAVLT immediate recall as the dependent variable. Gender, age,
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ethnicity, education, and APOE status were used as covariates to control for individual
differences.
Left entorhinal cortex tau level and RAVLT delayed recall score. A two-way
ANCOVA was conducted, with tau level in the left entorhinal cortex and SMI group as
independent variables, and RAVLT delayed recall as the dependent variable. Gender, age,
ethnicity, education, and APOE status were used as covariates to control for individual
differences.
Right entorhinal cortex tau level and RAVLT delayed recall score. A two-way
ANCOVA was conducted, with tau level in the right entorhinal cortex and SMI group as
independent variables, and RAVLT delayed recall as the dependent variable. Gender, age,
ethnicity, education, and APOE status were used as covariates to control for individual
differences.
Left hippocampus tau level and RAVLT delayed recall score. A two-way ANCOVA
was conducted, with tau level in the left hippocampus and SMI group as independent variables,
and RAVLT delayed recall as the dependent variable. Gender, age, ethnicity, education, and
APOE status were used as covariates to control for individual differences.
Right hippocampus tau level and RAVLT delayed recall score. A two-way ANCOVA
was conducted, with tau level in the right hippocampus and SMI group as independent variables,
and RAVLT delayed recall as the dependent variable. Gender, age, ethnicity, education, and
APOE status were used as covariates to control for individual differences.
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Left entorhinal cortex tau level and WMS-IV Logical Memory I score. A two-way
ANCOVA was conducted, with tau level in the left entorhinal cortex and SMI group as
independent variables, and WMS-IV Logical Memory I score as the dependent variable. Gender,
age, ethnicity, education, and APOE status were used as covariates to control for individual
differences.
Right entorhinal cortex tau level and WMS-IV Logical Memory I score. A two-way
ANCOVA was conducted, with tau level in the right entorhinal cortex and SMI group as
independent variables, and WMS-IV Logical Memory I score as the dependent variable. Gender,
age, ethnicity, education, and APOE status were used as covariates to control for individual
differences.
Left hippocampus tau level and WMS-IV Logical Memory I score. A two-way
ANCOVA was conducted, with tau level in the left hippocampus and SMI group as independent
variables, and WMS-IV Logical Memory I score as the dependent variable. Gender, age,
ethnicity, education, and APOE status were used as covariates to control for individual
differences.
Right hippocampus tau level and WMS-IV Logical Memory I score. A two-way
ANCOVA was conducted, with tau level in the right hippocampus and SMI group as
independent variables, and WMS-IV Logical Memory I score as the dependent variable. Gender,
age, ethnicity, education, and APOE status were used as covariates to control for individual
differences.
Left entorhinal cortex tau level and WMS-IV Logical Memory II score. A two-way
ANCOVA was conducted, with tau level in the left entorhinal cortex and SMI group as
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independent variables, and WMS-IV Logical Memory II score as the dependent variable.
Gender, age, ethnicity, education, and APOE status were used as covariates to control for
individual differences.
Right entorhinal cortex tau level and WMS-IV Logical Memory II score. A two-way
ANCOVA was conducted, with tau level in the right entorhinal cortex and SMI group as
independent variables, and WMS-IV Logical Memory II score as the dependent variable.
Gender, age, ethnicity, education, and APOE status were used as covariates to control for
individual differences.
Left hippocampus tau level and WMS-IV Logical Memory II score. A two-way
ANCOVA was conducted, with tau level in the left hippocampus and SMI group as independent
variables, and WMS-IV Logical Memory II score as the dependent variable. Gender, age,
ethnicity, education, and APOE status were used as covariates to control for individual
differences.
Right hippocampus tau level and WMS-IV Logical Memory II score. A two-way
ANCOVA was conducted, with tau level in the right hippocampus and SMI group as
independent variables, and WMS-IV Logical Memory II score as the dependent variable.
Gender, age, ethnicity, education, and APOE status were used as covariates to control for
individual differences. The Benjamini-Hochburg method (B-H; Benjamini & Hochberg, 1995),
which controlled for a false discovery rate of α = .05, was utilized as a method of controlling for
Type I error, while also circumventing Type II errors (false discovery). All p-values were ranked
from smallest to largest and compared to B-H critical values. The largest p value which was
smaller than the B-H critical value (and all subsequently smaller p-values) were considered
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statistically significant. Thus, analyses were only considered significant when their p-value was
less than .005.
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CHAPTER III: RESULTS
Assumptions
Preliminary analyses were performed for all variables to ensure no violation of the
assumptions of level of measurement, random sampling, independence of observation,
normal distribution, and homogeneity of variance. Each of the dependent variables were
continuous variables. After review of the dependent variables and their relationship with each
other, independence of observation was met for each measure.
Normality was assessed via values of skewness and kurtosis. Table 2 displays
violations of the assumption of normality for dependent variables. When assessing skewness
and kurtosis for normality, a nonparametric test may be used in place of a parametric test (i.e.
ANOVA). However, no nonparametric test exists to replace ANCOVA analyses; that is,
there is not a reliable nonparametric test which controls for covariates in the analysis. Per
Stevens (2012), “skewness has only a slight effect (generally only a few hundredths) on the
alpha level or power” and “the effects of kurtosis on level of significance, although greater,
also tend to be slight” (p. 224). Thus, ANCOVA analyses were run, with assumptions
specific to ANCOVAs assessed for each analysis (see below for detailed information for
each variable), and strict significance value used to circumvent Type I and Type II error.
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Table 2.
Normality of variables
Variable
EF Composite
Trials A
Trails B
Clock
Category Fluency
Memory Composite
RAVLT Immediate
RAVLT Delay
WMS-IV LM I
WMS-IV LM II

Min

Max

Skewness

Kurtosis

-.81
15.00
31.00
3.00
12.00
-.16
0.00
0.00
4.00
4.00

2.99
65.00
220.00
5.00
55.00
.79
15.00
15.00
25.00
25.00

.19
.86
1.87
-2.03
1.73
.70
-.25
-.20
-.41
-.33

-.39
.67
4.34
3.43
7.74
.91
-.58
-.69
3.40
.34

KolmogorovSmirnov
.09
.10
.18
.48
.11
.08
.10
.07
.08
.10

Sig.
.023*
.004*
.000*
.000*
.002*
.069
.006*
.089
.044*
.008*

EF= Executive Functioning; WMS-IV = Wechsler Memory Scale- Fourth Edition;
LM=Logical Memory; RAVLT = Rey Auditory Verbal Learning Test; Trails = Trail Making
Test; *p < 0.05
EF Composite.
Normality was assessed for the continuous outcome variable of EF Composite (M =
1.09, SD = .08). Using the 5% trimmed mean (1.08) compared to the original mean (1.09), it
was determined that there were not any extreme values influencing the mean of the data. The
value for skew (.19) indicated normal distribution as it was far from 1.00. The value for
kurtosis (-.39) did not indicate abnormal distribution. The K-S value (K-S = .09; p = .02) was
significant, however review of a histogram supported a normal distribution of scores on the
EF Composite (see Figure 1). Furthermore, a boxplot of the scores indicated there were no
outliers (see Figure 2). After running the one-way between-groups ANCOVA, homogeneity
of variance was assessed using Levene’s statistic (p = .40), and it was determined that the
homogeneity of variance assumption was not violated because it was greater than the p > .05
cut-off value.
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Figure 1. Histogram showing distribution of EF Composite for the total sample

Figure 2. Boxplot showing outliers of Executive Function Composite for the total sample
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Trail Making A.
Normality was assessed for the continuous outcome variable Trail Making A (M =
30.83, SD = 9.53). Using the 5% trimmed mean (30.27) compared to the original mean
(30.83), it was determined that there were not any extreme values influencing the mean of the
data. The value for skew (.86) indicated possible abnormal distribution. The value for
kurtosis (.67) also indicated possible abnormal distribution. The K-S value (K-S = .10; p =
.004) was significant, suggesting that the distribution was abnormal. A histogram confirmed
a positively skewed distribution of scores (see Figure 3), with review of a boxplot of the
scores identifying 3 possible outliers which may be impacting distribution of this variable
(see Figure 4). After running the one-way between-groups ANCOVA, homogeneity of
variance was assessed using Levene’s statistic (p = .93), and it was determined that the
homogeneity of variance assumption was not violated because it was greater than the p > .05
cut-off value.
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Figure 3. Histogram showing distribution of Trails A for the total sample

Figure 4. Boxplot showing outliers of Trails A for the total sample
Trail Making B.
Normality was assessed for the continuous outcome variable of Trail Making B (M =
73.91, SD = 33.70). Using the 5% trimmed mean (70.21) compared to the original mean
(73.91), it was determined that there may be values influencing the mean of the data. The
value for skew (1.87) and kurtosis (4.34) indicated abnormal distribution. The K-S value (KS = .18; p = .000) was significant, suggesting that the distribution was abnormal. A histogram
confirmed the abnormal distribution of scores (Figure 5) and a boxplot of the scores indicated
outliers (see Figure 6). After running the one-way between-groups ANCOVA, homogeneity
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of variance was assessed using Levene’s statistic (p = .82), and it was determined that the
homogeneity of variance assumption was not violated.

Figure 5. Histogram showing distribution of Trails B for the total sample
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Figure 6. Boxplot showing outliers of Trails B for the total sample
Clock.
Normality was assessed for the continuous outcome variable of clock (M = 4.78, SD
= .47). Using the 5% trimmed mean (4.84) compared to the original mean (4.78), it was
determined that there were not any extreme values influencing the mean of the data. The
value for skew (-2.03), kurtosis (3.43), and the K-S value (K-S = .48; p = .000) suggest the
distribution was abnormal. A histogram confirmed the normal distribution of scores on the
clock were negatively skewed (see Figure 7). After running the one-way between-groups
ANCOVA, homogeneity of variance was assessed using Levene’s statistic (p = .58), and it
was determined that the homogeneity of variance assumption was not violated.

Figure 7. Histogram showing distribution of clock scores for the total sample
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Category Fluency Test.
Normality was assessed for the continuous outcome variable of Category Fluency test
(M = 21.99, SD = 5.79). Using the 5% trimmed mean (21.63) compared to the original mean
(21.99), it was determined that there were not any extreme values influencing the mean of the
data. The value for skew (1.73) and kurtosis (7.74) indicated abnormal distribution. The K-S
value (K-S = .11; p = .002) was significant, suggesting that the distribution was abnormal. A
histogram confirmed the positive skew of scores on the Category Fluency Test (see Figure
8). Furthermore, a boxplot of the scores indicated there were two possible outliers (see Figure
9). After running the one-way between-groups ANCOVA, homogeneity of variance was
assessed using Levene’s statistic (p = .995), and it was determined that the homogeneity of
variance assumption was not violated because it was greater than the p > .05 cut-off value.

Figure 8. Histogram showing distribution of category fluency for the total sample
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Figure 9. Boxplot showing outliers of category fluency recall
Memory Composite.
Normality was assessed for the continuous outcome variable of the memory
composite score (M = 1.01, SD = .58). Using the 5% trimmed mean (.992) compared to the
original mean (1.01), it was determined that there were not any extreme values influencing
the mean of the data. The value for skew (.70) indicated normal distribution. The value for
kurtosis (.91) indicated possible abnormal distribution. The K-S value (K-S = .08; p = .069)
was not significant, suggesting that the distribution was normal. A histogram confirmed the
normal distribution of scores on the Category Fluency Test (see Figure 10). A boxplot of the
scores indicated there 2 possible outliers which likely related to possible kurtosis findings
(see Figure 11). After running the one-way between-groups ANCOVA, homogeneity of
variance was assessed using Levene’s statistic (p = .383) and it was determined that the
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homogeneity of variance assumption was not violated because it was greater than the p > .05
cut-off value.

Figure 10. Histogram showing distribution of memory composite for the total sample
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Figure 11. Boxplot showing outliers of memory composite

RAVLT Immediate Recall.
Normality was assessed for the continuous outcome variable of RAVLT Immediate
Recall (M = 9.67, SD = 3.42). Using the 5% trimmed mean (9.76) compared to the original
mean (9.67), it was determined that there were not any extreme values influencing the mean
of the data. The value for skew (-.25) indicated normal distribution due to it being far from
1.00. The value for kurtosis (-.58) did not indicate abnormal distribution. The K-S value (K-S
= .10; p = .006) was significant, suggesting that the distribution may be abnormal. A
histogram confirmed a negatively skewed distribution of scores on RAVLT Immediate
Recall scores (see Figure 12). However, a boxplot of the scores indicated there were no
outliers (see Figure 13). After running the one-way between-groups ANCOVA, homogeneity
of variance was assessed using Levene’s statistic (p = .142), and it was determined that the
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homogeneity of variance assumption was not violated because it was greater than the p > .05
cut-off value.

Figure 12. Histogram showing distribution of RAVLT immediate recall for the total sample
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Figure 13. Boxplot showing outliers of RAVLT immediate recall
RAVLT Delay Recall.
Normality was assessed for the continuous outcome variable of RAVLT Delayed
Recall (M = 8.17, SD = 4.05). Using the 5% trimmed mean (8.24) compared to the original
mean (8.17), it was determined that there were not any extreme values influencing the mean
of the data. The value for skew (-.20) indicated normal distribution. The value for kurtosis (.69) did not indicate abnormal distribution. The K-S value (K-S = .07; p = .089) was not
significant, suggesting that the distribution was normal. A histogram confirmed the normal
distribution of scores on the Category Fluency Test (see Figure 15). Furthermore, a boxplot
of the scores indicated there were no outliers (see Figure 16). After running the one-way
between-groups ANCOVA, homogeneity of variance was assessed using Levene’s statistic
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(p = .132) and it was determined that the homogeneity of variance assumption was not
violated because it was greater than the p > .05 cut-off value.

Figure 14. Histogram showing distribution of RAVLT delay recall for the total sample
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Figure 15. Boxplot showing outliers of RAVLT delay recall
LM Immediate Recall.
Normality was assessed for the continuous outcome variable of WMS-IV Logical
Memory Immediate Recall (M = 15.89, SD = 3.47). Using the 5% trimmed mean (15.98)
compared to the original mean (15.89), it was determined that there were not any extreme
values influencing the mean of the data. The value for skew (-.41) indicated normal
distribution and the value for kurtosis (.34) did not indicate abnormal distribution. The K-S
value (K-S = .08; p = .044) was significant, suggesting that the distribution may be abnormal.
A histogram confirmed a normal distribution of scores on the WMS-IV Logical Memory
Immediate Recall (see Figure 16). A boxplot of the scores indicated there were 2 possible
outliers (see Figure 17). After running the one-way between-groups ANCOVA, homogeneity
of variance was assessed using Levene’s statistic (p = .343) and it was determined that the
homogeneity of variance assumption was not violated because it was greater than the p > .05
cut-off value.
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Figure 16. Histogram showing distribution of WMS-IV immediate recall for the total sample

Figure 17. Boxplot showing outliers of WMS-IV Logical memory immediate recall
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LM Delay Recall.
Normality was assessed for the continuous outcome variable of WMS-IV Logical
Memory Delay Recall (M = 14.69, SD = 3.70). Using the 5% trimmed mean (14.79)
compared to the original mean (14.69), it was determined that there were not any extreme
values influencing the mean of the data. The value for skew (-.33) indicated normal
distribution due to it being far from 1.00. The value for kurtosis (.34) did not indicate
abnormal distribution. The K-S value (K-S = .10; p = .008) was significant, suggesting a
possibly abnormal distribution. Review of a histogram confirmed a normal distribution of
scores on the WMS-IV Logical Memory Delay Recall (see Figure 18). A boxplot of the
scores indicated there 2 possible outliers (see Figure 19). After running the one-way
between-groups ANCOVA, homogeneity of variance was assessed using Levene’s statistic
(p = .076) and it was determined that the homogeneity of variance assumption was not
violated because it was greater than the p > .05 cut-off value.
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Figure 18. Histogram showing distribution of WMS-IV delay recall for the total sample

Figure 19. Boxplot showing outliers of WMS-IV Logical memory delay recall
Participant Characteristics.
A chi-square test for independence indicated no significant association between SMI
and nSMI for gender, χ2 (1, N = 125) = 1.39, p = .24, phi = .13, ethnicity, χ2 (1, N = 125) =
1.04, p = .90, phi = .09, or APOE ɛ4 status, χ2 (1, N = 125) = 1.04, p = .31, phi = .09.
An independent samples t-test indicated no significant difference between SMI and
nSMI for age, t(123) = 1.79, p = .08, with a small effect size (η2 = .03).
An independent samples t-test indicated no significant difference between SMI and
nSMI for level of education t(123) = -.37, p = .71, with a small effect size (η2 = .001).
Analyses by research question
Research Question I: Subjective Memory Impairment and Cognitive Measures
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One-way analyses of covariance (ANCOVAs) were run to compare SMI to nSMI on
each cognitive neuropsychological measure (EF composite score, Trails A, Trials B, clock
drawing, category fluency, memory composite score, RAVLT immediate recall, RAVLT
delayed recall, WMS-IV Logical Memory I and WMS-IV Logical Memory II). For the
current study, each possible covariate was included in every analysis in attempt to reduce the
impact of confounding factors. Building a model that included all covariates increased
robustness and decreased the possibility of Type 1 error. Levene’s tests and normality checks
were carried out and the assumptions met for each analysis.
Detailed information, including mean scores by group for all variables and statistical
findings, is provided in Table 3.
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Table 3.
SMI (n = 20) versus nSMI (n = 107) for Neuropsychological Domains, SUVR, and Analyses
SMI

nSMI

F

df

ηp2

p

0.83 (.68)

1.13 (.90)

4.04

115

.06

.007

Trails A

31.20 (8.61)

30.76 (9.73)

1.31

114

.01

.255

Trails B

81.05 (25.47) 72.55 (34.99)

3.39

113

.03

.068

Executive Function Domain
EF Composite Score

Clock Drawing

4.80 (.41)

4.77 (.48)

0.00

114

.00

.962

20.60 (4.83)

22.25 (5.93)

3.80

115

.03

.054

Memory Composite Score

1.15 (.66)

.99 (.56)

.03

114

.00

.866

RAVLT Immediate Recall

10.68 (3.32)

9.49 (3.42)

1.04

114

.01

.309

RAVLT Delayed Recall

9.15 (4.27)

7.93 (4.01)

.43

115

.00

.516

WMS-IV LM I

15.55 (3.94)

15.95 (3.40)

.45

115

.00

.505

WMS-IV LM II

14.25 (3.89)

14.77 (3.68)

.61

115

.01

.436

Left Entorhinal Tau SUVR

1.11 (.19)

1.11 (.12)

.02

115

.00

.886

Right Entorhinal Tau SUVR

1.09 (.14)

1.11 (.14)

.02

115

.00

.886

Left Hippocampus Tau
SUVR

1.22 (.21)

1.21 (.15)

.16

115

.00

.689

Right Hippocampus Tau
SUVR

1.22 (.19)

1.21 (.16)

.150

115

.00

.701

Category Fluency
Memory Domain

Tau Measurements

Note. Mean (SD); df = degrees of freedom, ηp2 = partial eta squared effect size, * = significant at
the .005 level.

51
Executive function domains. There was not a significant difference between SMI and
nSMI participants on EF composite scores (F(1, 115) = 4.04, p = .007, ηp2 = .06) when
controlling for B-H. While not statistically significant, the estimated marginal means for
participants with SMI (M = .40) were lower scores than composite score for the nSMI group (M
= .90) after adjusting for the covariates. Figure 21 shows EF scores by group.
he ANCOVA comparing SMI and nSMI indicated no significant differences on Trails A (F(1,
114) = 1.31, p = .255, ηp2 = .01); Trails B (F(1, 113) = 3.39, p = .068, ηp2 = .03); clock drawing,
(F(1, 114) = .00, p = .962, ηp2 = .00); or category fluency (F(1, 115) = 3.80, p = .054, ηp2 = .03).
When comparing the estimated marginal means, participants with SMI had higher Trails A (M =
38.17) and Trails B (M = 98.57) scores than participants without SMI (Trails A: M = 35.86;
Trials B: M = 85.11), and those with SMI showed lower clock drawing (M = 4.66) and category
fluency (M = 19.11) than participants without SMI (clock drawing: M = 4.67; category fluency:
M = 21.84), though these differences did not reach significant levels. Figure 20 displays scores
by group for each EF neuropsychological assessment.
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Figure 20. Distribution of EF composite score, Trails A and B, clock drawing, and category fluency, by SMI group
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Memory domains. There was not a significant difference for SMI and nSMI patients
on memory composite scores (F(1, 114) = .03, p = .866, ηp2 = .00). Additionally, no
significant differences between SMI and nSMI groups were found for scores on RAVLT
immediate recall (F(1, 114) = 1.04, p = .309, ηp2 = .01); RAVLT delayed recall (F(1, 115) =
.43, p = .516, ηp2 = .00); Logical Memory I (F(1, 115) = .45, p = .505, ηp2 = .00); or Logical
Memory II (F(1, 115) = .61, p = .436, ηp2 = .01). Comparing the estimated marginal means
showed that those with SMI had higher memory composite scores (M = .84), higher RAVLT
immediate recall scores (M = 10.48), and higher RAVLT delayed recall scores (M = 8.77),
than participants without SMI (memory composite: M = .81; RAVLT immediate recall: M =
9.64; RAVLT delayed recall: M = 8.16), though not to a significant level. However, while
still not to a significant level, participants with SMI showed lower estimated marginal means
for Logical Memory I (M = 15.97) and Logical Memory II (M = 14.74) than participants
without SMI (Logical Memory I: M = 16.55; Logical Memory II: M = 15.47). Figure 21
displays scores for each memory test.
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Figure 21. Distribution of Memory composite score, RAVLT, and WS-IV LM I and II, by SMI group
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Research Question II: Subjective Memory Complaint and Biomarker Level
One-way ANCOVAs were conducted between SMI and nSMI groups to compare tau
binding in the left and right entorhinal cortices and the left and right hippocampi, while
controlling for possible confounding variables (gender, age, education, ethnicity, and APOE
status). Levene’s test and normality checks were carried out and the assumptions met.
Entorhinal cortices and SMI. There were no significant differences for SMI and
nSMI participants in tau binding in the left entorhinal cortex (F(1, 115) = .02, p = .886, ηp2 =
.00) or right entorhinal cortex (F(1, 115) = .02, p = .886, ηp2 = .00). Figures 22 and 23 show
distribution of SUVR for left and right entorhinal regions, by SMI and nSMI group.

Figure 22. Histogram showing distribution of left entorhinal SUVR, by group
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Figure 23. Histogram showing distribution of right entorhinal SUVR, by group
Hippocampi and SMI. There were no significant differences between SMI and nSMI
groups in tau binding in the left (F(1, 115) = .16, p = .689, ηp2 = .00) or right (F(1, 115) = .15,
p = .701, ηp2 = .00) hippocampi. Figures 24 and 25 show SMI and nSMI grouping
distributions of SUVR for left and right hippocampi.
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Figure 24. Histogram showing distribution of left hippocampus SUVR, by group

Figure 25. Histogram showing distribution of right hippocampus SUVR, by group
Research Question III: Subjective Memory Impairment, Tau Level, and
Memory Measures
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A two-way ANCOVA was conducted to determine if differences between SMI and
nSMI groups in level of tau binding in the left and right entorhinal cortices and left and right
hippocampi interacted with memory performance. Specifically, the neuropsychological
memory domains included the memory composite, RAVLT immediate recall, RAVLT
delayed recall, WMS-IV Logical Memory I, and WMS-IV Logical Memory II scores.
Analyses for each domain were run separately. Gender, age, ethnicity, education, and APOE
ɛ4 status were again used as covariates to control for individual differences. Preliminary
checks were conducted to ensure that there were no violations of assumptions of normality,
linearity, homogeneity of variances, homogeneity of regression slopes, and reliable
measurement of the covariate.
Memory composite. There was not a significant interaction effect for SMI and
memory composite (F(1, 98) = 2.66, p = .106, ηp2 = .03) after adjusting for left entorhinal tau
level. There were no main effects for SMI (F(1, 98) = .10, p = .757, ηp2 = .00) and when
controlling for the B-H method, the main effect for left entorhinal tau level did not reach
significance (F(1, 98) = 5.55, p = .021, ηp2 = .05). There was not a significant interaction
effect for SMI and memory composite scores (F(1, 98) = .75, p = .390, ηp2 = .01) after
adjusting for right entorhinal tau level. Again, neither main effect were statistically
significant (SMI: F(1, 99) = 2.77, p = .099, ηp2 = .03; right entorhinal tau level: F(1, 98) =
6.21, p = .014, ηp2 = .06). Estimated marginal means for memory composite scores, SMI, and
entorhinal tau level are seen in Figures 26 and 27.
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Figure 26. Line graph of memory composite estimated marginal means by SMI presence,
when adjusting for left entorhinal tau level

Figure 27. Line graph of memory composite estimated marginal means by SMI presence,
when adjusting for right entorhinal tau level

60
There was not a significant interaction effect for SMI and memory composite (F(1,
97) = 1.73, p = .191, ηp2 = .02) after adjusting for left hippocampus tau level. The main
effects for SMI (F(1, 97) = .20, p = .654, ηp2 = .00) and left hippocampus tau level (F(1, 97)
= 1.77, p = .186, ηp2 = .02) were not significant. There was not a significant interaction effect
for SMI and memory composite (F(1, 97) = 1.51 p = .223, ηp2 = .02) after adjusting for right
hippocampus tau level, and neither main effect for SMI (F(1, 97) = .30, p = .583, ηp2 = .00)
or right hippocampus tau level (F(1, 97) = 1.26, p = .265, ηp2 = .01) were significant (see
Figures 28 and 29).

Figure 28. Line graph of memory composite estimated marginal means by SMI presence,
when adjusting for left hippocampus entorhinal tau level
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Figure 29. Line graph of memory composite estimated marginal means by SMI presence,
when adjusting for right hippocampus entorhinal tau level

RAVLT immediate recall. There was not a significant interaction effect for SMI and
RAVLT immediate recall (F(1, 98) = 2.92, p = .091, ηp2 = .03) when adjusting for left
entorhinal tau level. The main effect for SMI (F(1, 98) = .01, p = .943, ηp2 = .00) and left
entorhinal tau level (F(1, 98) = 2.47, p = .119, ηp2 = .03) were not significant. For these same
variables (SMI and RAVLT immediate recall), adjusting for right entorhinal tau level did not
result in significant interaction effects (F(1, 98) = .33, p = .564, ηp2 = .00) or a main
interaction effect for SMI (F(1, 98) = .45, p = .506, ηp2 = .01). After controlling via the B-H
method, there was not a significant main effect for right entorhinal tau level and RAVLT
immediate recall (F(1, 98) = 5.83, p = .018, ηp2 = .06; see Figures 30 and 31).
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Figure 30. Line graph of RAVLT immediate recall estimated marginal means by SMI
presence, when adjusting for left entorhinal tau level

Figure 31. Line graph of RAVLT immediate recall estimated marginal means s by SMI
presence, when adjusting for right entorhinal tau level
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There was not a significant interaction effect for SMI and RAVLT immediate recall
(F(1, 97) = 2.09, p = .152, ηp2= .02) after adjusting for left hippocampus tau level. The main
effect for SMI (F(1, 97) = .59, p = .446 ηp2 = .01) and for left hippocampus tau level (F(1,
97) = .61, p = .437, ηp2 = .01) were not significant. Interaction (F(1, 97) = 1.18, p = .281, ηp2=
.01) and main effects (SMI: F(1, 97) = .78, p = .379, ηp2 = .01; right hippocampus tau level
F(1, 97) = .42, p = .520, ηp2 = .00) did not reach significance when adjusted for right
hippocampus tau level. Figures 32 and 33 show estimated marginal means for these effects.

Figure 32. Line graph of RAVLT immediate recall estimated marginal means by SMI
presence, when adjusting for left hippocampus tau level
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Figure 33. Line graph of RAVLT immediate recall estimated marginal means by SMI
presence, when adjusting for right hippocampus tau level

RAVLT delayed recall. There was not a significant interaction effect for SMI and
RAVLT delayed recall (F(1, 99) = 1.72 p = .193, ηp2 = .02) after adjusting for left entorhinal
tau level. The main effect for SMI (F(1, 99) = .15, p = .700, ηp2 = .00) was not significant,
and the main effect for left entorhinal tau level (F(1, 99) = 5.37, p = .023, ηp2 = .05) did not
survive the B-H method. There was not a significant interaction effect for SMI and RAVLT
delayed recall (F(1, 99) = .15, p = . 702, ηp2 = .00) when adjusted for right entorhinal tau
level. Again, the main effect for SMI (F(1, 99) = .68, p = .411, ηp2 = .01) was not significant,
and the main effect for right entorhinal tau level (F(1, 99) = 8.36, p = .005, ηp2 = .08) did not
survive the B-H method (see Figures 34 and 35).
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Figure 34. Line graph of RAVLT delayed recall estimated marginal means by SMI presence,
when adjusting for left entorhinal tau level

Figure 35. Line graph of RAVLT delayed recall estimated marginal means by SMI presence,
when adjusting for right entorhinal tau level
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There was not a significant interaction effect for SMI and RAVLT delayed recall
(F(1, 98) = 2.77, p = .099, ηp2 = .03) after adjusting for left hippocampus tau level. The main
effect for SMI was not significant (F(1, 98) = 1.03, p = .312, ηp2 = .01) and the main effect
for left entorhinal tau level (F(1, 98) = 4.74, p = .032, ηp2 = .05), did not reach significance
once the B-H method was applied (see Figure 36).
There was not a significant interaction effect for SMI and RAVLT delayed recall
(F(1, 98) = 2.33, p = .130, ηp2 = .02) after adjusting for right hippocampus tau level,. The
main effect for SMI was not significant (F(1, 98) = 1.52, p = .221, ηp2 = .02) and the main
effect for right hippocampus tau level (F(1, 98) = 5.13, p = .026, ηp2 = .05) did not survive
application of the B-H method (see Figure 37).
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Figure 36. Line graph of RAVLT delayed recall estimated marginal means by SMI presence,
when adjusting for left hippocampus tau level

Figure 37. Line graph of RAVLT delayed recall estimated marginal means by SMI presence,
when adjusting for right hippocampus tau level
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WMS-IV Logical Memory I. The interaction effect for SMI and Logical Memory I,
when adjusted for left entorhinal tau level, was not significant (F(1, 99) = 6.48, p = .012, ηp2
= .06) after the B-H method was applied. The main effect for SMI (F(1, 99) = .30, p = .587,
ηp2 = .00) was not significant; however, the main effect for left entorhinal tau level (F(1, 99)
=10.47, p = .002, ηp2 = .10) was significant and indicated a difference in Logical Memory I
scores for low versus high levels of tau. There was not a significant interaction effect for SMI
and Logical Memory I after adjusting for right entorhinal tau level (F(1, 99) = 3.47, p = .065,
ηp2 = .03). The main effect for SMI (F(1, 99) = .07, p = .788, ηp2 = .00) was not significant.
However, the main effect for right entorhinal tau level was significant (F(1, 99) = 15.93, p =
.000, ηp2 = .14). Figures 38 and 39 show these effects.

Figure 38. Line graph of WMS-IV Logical Memory I estimated marginal means by SMI
presence, when adjusting for left entorhinal tau level
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Figure 39. Line graph of WMS-IV Logical Memory I estimated marginal means by SMI
presence, when adjusting for right entorhinal tau level
When applying the B-H method, there was not a significant interaction effect for SMI
and Logical Memory I after adjusting for left hippocampus tau level (F(1, 98) = 4.84, p =
.030, ηp2 = .05). The main effect for SMI, F(1, 98) = .376, p = .541, ηp2 = .004, was not
significant, however left hippocampus tau level (F(1, 98) = 10.03, p = .002, ηp2 = .09), was
significant when utilizing B-H values. There was not a significant interaction effect (F(1, 98)
= 4.69, p = .033, ηp2 = .05), after right hippocampus tau level adjustment, but there was a
significant main effect for right hippocampus tau level (F(1, 98) = 10.13, p = .002, ηp2 = .09).
There was no significant main effect for SMI (F(1, 98) = .46, p = .500, ηp2 = .01; see Figures
40 and 41).
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Figure 40. Line graph of WMS-IV Logical Memory I estimated marginal means by SMI
presence, when adjusting for left hippocampus tau level

Figure 41. Line graph of WMS-IV Logical Memory I estimated marginal means by SMI
presence, when adjusting for right hippocampus tau level
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WMS-IV Logical Memory II. There was not a significant interaction effect for SMI
and Logical Memory II after adjustment for left entorhinal tau level (F(1, 99) = 6.69, p =
.011, ηp2 = .06). The main effect for SMI was not significant (F(1, 99) = 2.46, p = .120, ηp2 =
.02). There was not a significant main effect for left entorhinal tau level (F(1,99) = 7.77, p =
.006, ηp2 = .07). While there was no interaction effect (F(1, 99) = 2.94, p = .090, ηp2 = .03),
after adjusting for right entorhinal tau level, there was a main effect for right entorhinal tau
level (F(1, 99) = 11.52, p = .001, ηp2 = .10), after applying the B-H method, indicating a
difference in Logical Memory II scores based on low versus high levels of tau in the right
entorhinal cortex (see Figures 42 and 43).

Figure 42. Line graph of WMS-IV Logical Memory II estimated marginal means by SMI
presence, when adjusting for left entorhinal tau level
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Figure 43. Line graph of WMS-IV Logical Memory II estimated marginal means by SMI
presence, when adjusting for right entorhinal tau level
Finally, there was not a significant interaction effect of SMI and Logical Memory II
(F(1, 98) = 1.42, p = .237, ηp2 = .01) after adjusting for left hippocampus tau level. The main
effect for SMI (F(1, 98) = .01, p = .920, ηp2 = .00) and left hippocampus tau level (F(1, 98) =
6.09, p = .015, ηp2 = .06) was not significant. There was not a significant interaction effect for
SMI and Logical Memory II after adjusting for right hippocampus tau level (F(1, 98) = 1.94,
p = .167, ηp2 = .02). The main effect for SMI was not significant (F(1, 98) = .05, p = .820, ηp2
= .00) and the main effect for right hippocampus tau level was not significant (F(1, 98) =
6.74, p = .011, ηp2 = .06). Figures 44 and 45 depict the effects for these analyses.
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Figure 44. Line graph of WMS-IV Logical Memory II estimated marginal means by SMI
presence, when adjusting for left hippocampus tau level

Figure 45. Line graph of WMS-IV Logical Memory II estimated marginal means by SMI
presence, when adjusting for right hippocampus tau level
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CHAPTER IV: DISCUSSION
Findings
The aims of the current study were threefold; First, I assessed neuropsychological
functioning in a sample of clinically normal participants with and without SMI, to determine
if there were differences between groups in the cognitive domains of executive function and
memory. Second, I examined if level of tau AV-1451 binding in the hippocampi or
entorhinal cortices differed between SMI and nSMI individuals. Finally, I determined if
presence of SMI and level and location of tau AV-1451 binding in these regions revealed
significant differences in memory performance between SMI and nSMI groups.
Importantly, my participant pool did not differ in terms of demographic data (gender,
ethnicity, age, or education level), or in APOE ɛ4 status. Though not found to be significantly
different between groups, these possible confounding variables were included as covariates
in all analyses, allowing for results to be as specific to my research questions as possible. To
limit possible type I or type II errors, I employed a strict false discovery rate procedure, the
Benjamini-Hochburg algorithm. From utilization of scientific analyses and stringent alpha
levels, the resulting data and conclusions drawn are appropriate to the task of assessing
mediation of SMI, neuropsychological functioning, and tau binding in a clinically normal
sample.
Overall, no differences were found between groups within the cognitive domains of
executive functioning or memory when separated by SMI, in support of my first hypothesis.
When analyzing levels of tau in the hippocampi and entorhinal cortices, no significant
differences were found between groups, and did not support my second hypotheses. When
separating groups by SMI and low/high levels of tau in each brain region, no significant
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interaction effects were discovered. However, there were significant main effects for tau
level and location (left/right entorhinal cortices and left/right hippocampi) for the Wechsler
Memory Scale-IV Logical Memory I test, and in the left entorhinal cortex for Logical
Memory II, supporting differences in level of AV-1451 tau binding for story memory in
these regions.
Executive functioning in SMI and nSMI groups. Data supported my first research
question, which asserted participant performance in the domain of executive function would
not differ between groups. Additionally, for each hypothesis within this research question,
including assessing EF composite score as well as specific neuropsychological tests (e.g.
Trails A and B, clock drawing, and category fluency), data showed there were no significant
differences in any EF task between SMI or nSMI groups.
Data supporting insignificant variability in EF between groups is an important
consideration, given the underlying foundation of SMI. SMI, while varied in the literature, is
commonly determined based solely on a single self-report question, which asks participants
to reflect on their own view of changes in their memory (Abdulrab & Heun, 2008). Had
participants differed in terms of executive functioning, an argument could be made that
individuals are not at full capacity to be aware of or able to assess their own memory
function (Stenfors, Marklund, Hanson, Theorell, & Nilsson, 2013). As my groups did not
differ in EF performance, and did not show impaired EF as per the ADNI3 criteria for CN
group selection, I concluded that my sample was capable of assessing their own memory
changes. Current findings also support previous work which suggested individuals with
memory changes which are not detectable by current neuropsychological assessment have
insight into their own specific memory decline (Bäckman et al., 2005).
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Memory in SMI and nSMI groups. Hypotheses within my first research question
assessed memory functioning in SMI and nSMI groups. I anticipated that splitting the overall
CN sample into SMI and nSMI groups would allow for discovery of specific differences
between groups which would not be otherwise detectable. My hypotheses aimed to determine
differences between groups on memory composite scores, as well as list learning (RAVLT
immediate recall and RAVLT delayed recall) and story memory (WMS-IV Logical Memory
I and Logical Memory II). I hypothesized there would be a significant difference between
groups on each of these factors, with participants with SMI showing significantly worse
memory scores than participants without SMI. Data showed no significant differences
between groups on any memory tasks, leading to rejection of these hypotheses.
Given the stringent requirements for cognitive impairment diagnosis by ADNI3
criteria, it follows that performance for those determined to be cognitively normal, as in my
sample group, may not vary enough to detect notable differences, even when separated by
subjective impairment. While previous research supports SMI can be an early sign of MCI or
AD development (Jessen et al., 2010), the current study did not find support for use of SMI
alone as diagnostic tool to assess memory change independent of neuropsychological
assessment.
Additionally, it is possible individuals who were high functioning prior to onset of
subjective memory difficulty may have had a decline in memory functioning, yet due to
higher premorbid functioning, cognitive reserve, and ability to compensate for these changes,
they fell in the average or “normal” range on testing (Stern, 2006). Thus, while these
individuals may have a decline in their memory consistent with the early stages of
neurocognitive decline leading to MCI or AD, it may not be to a level sensitive enough to

77
detect via neuropsychological measures or ADNI3 MCI criteria, and thus may have obscured
the homogeneity of the current “cognitively normal” sample.
Tau binding of AV-1451 in the entorhinal cortices and hippocampi. As previous
research has shown, while NFTs have been implicated in MCI or AD involvement (Dickson,
2004), so too is there a wealth of knowledge supporting tau as not solely specific to MCI or
AD, with various other existing tauopathies in which tau accumulation affects functioning
(Institute for Neurodegenerative Diseases, 2013). As AV-1451 is a newer biomarker which
has shown to be specific to AD tau binding, my research expanded on those of Schöll et al.
(2016), who found the AV-1451 biomarker related to impairment in global cognition in
healthy controls. My study looked at memory, a hallmark early deficit in AD, and provided
evidence that the AV-1451 biomarker may not significantly relate to memory in the
entorhinal cortices or hippocampi in healthy controls, when grouped solely by SMI.
Specifically, my second research question asked if binding of the tau AV-1451
biomarker differed between SMI and nSMI groups. I assessed AV-1451 tau SUVRs in
partial-volume corrected tau-PET imaging for each participant and analyzed binding in four
regions of the brain: left entorhinal cortex, right entorhinal cortex, left hippocampus, and
right hippocampus. My results did not detect differences in tau binding in any region
assessed between SMI and nSMI groups. From this, I can conclude that similarly to my
previous finding which showed presence of SMI is not specific enough to detect differences
in memory scores, neither is it specifically related to differences in level of tau binding alone
in the entorhinal cortices or hippocampi. Overall, level of tau related to SMI was not to a
significant enough level to be detected or supported via the current research study.
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Neuropsychological functioning and SMI, by level of tau AV-1451 binding. My
final research question looked at SMI and level of tau binding to assess differences in
neuropsychological performance and determine if these differences were mediated by level
and location of AV-1451 binding.
I hypothesized there would be significant differences between groups on memory
performance as mediated by tau level, location, and SMI presence. While analyses did not
show significant interaction effects for tau level and SMI on any memory measure, main
effects for Logical Memory I were significant for all regions of interest (ROI), and the main
effect for Logical Memory II and the right entorhinal cortex was significant.
Specifically, Logical Memory I estimated marginal means in all ROIs (left and right
entorhinal cortices and hippocampi) showed those with high AV-1451 tau binding had lower
Logical Memory I scores, indicating worse performance was related to higher level of tau.
Logical Memory II performance in participants with high level of binding of AV-1451 in the
left entorhinal cortex showed overall lower estimated marginal means (i.e., worse
performance) than did participants with low tau levels, indicating differences on this task are
again related to tau level in the left entorhinal cortex. Thus, significant differences in Logical
Memory I and II performances were associated with level of tau binding in the entorhinal
cortices and hippocampi.
Overall, though the first two research questions looking at differences between groups
on memory performance and tau binding independently were not supported, the current
findings indicated there is an effect of location and level of tau on Logical Memory I and II
performance. This finding provides support that differences on story memory tasks can be
seen when level of AV-1451 tau binding in the entorhinal cortices and the hippocampi are
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included in assessment, though this finding is not mediated by presence or absence of SMI. It
may be that group differences are too minute to detect solely by presence of tau or SMI
alone, but that low or high tau levels provide data on differences in immediate recall of a
story memory task. Logical memory has shown to be a useful diagnostic tool for memory
impairment (Lezak et al., 2012) and the current findings showed significant effect of tau level
on Logical Memory I and II performance. My research provides additional support for use of
WMS-IV Logical Memory as a beneficial diagnostic tool for detection of differences in tau
level for participants.
Strengths
The current research was one of the first to attempt to determine a relationship between the
novel AV-1451 biomarker and neuropsychological performance among cognitively normal
individuals with subjective memory impairment. The current study used a very strict false
discovery rate, in order to prevent inaccurate statistical results. Additionally, I included all
possible covariate in my analyses, utilizing all demographic variables as well as APOE Ɛ4
status in every analysis. Though researchers do not always do so, including these covariates
allowed for an even stricter assessment of the dependent variables in question. Current results
show a relationship between level of tau and story memory scores, which provides
researchers with support for further evaluation of story memory as a means of detecting tau
level in cognitively normal older adults (Ricci et al., 2012). Further, the current research
provides added evidence of contextual memory as a marker for tau level, which has widely
been implicated in progression from MCI to AD (Maass et al., 2017).
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Limitations
The first limitation to this study is that of diversity of participants. The ADNI3
database consists of a widely heterogenous participant group, with the current study sample
comprised of predominantly Caucasian, well-educated participants. Additionally, I only
assessed AV-1451 in two brain regions (bilaterally), which are largely related to memory
changes in AD. While I describe support for level of tau and its relationship to specific
neuropsychological assessments, these findings cannot be generalized to tau levels in other
brain regions, or other tau biomarkers.
Additional limitations to the current study are that of the small SMI group size, which
impacted power of my analyses, and the unequal sample sizes between groups. A larger,
more equivalent sample would help to increase power of each analysis and would facilitate
ability for identification of more nuanced differences and variability between groups for the
AV-1451 biomarker. Finally, the lack of a retrospective study limits my results. I cannot
conclude that these findings will lead to accurate detection of participants who will go on to
develop a neurodegenerative disorder, as I do not know which participants will develop MCI
or AD.
The current method for evaluating SMI followed previous research methodology,
which utilized a yes/no question modality (Abdulrab & Heun, 2008). This measure may not
have been sensitive or specific enough to complexly assess subjective memory impairment. I
did not include additional collateral information to reinforce notable memory changes in dayto-day life, which if utilized may have created a more stringent sample of SMI participants.
Additionally, the current research only assessed two cognitive domains (EF and
memory), and only memory was assessed in conjunction with tau and SMI concurrently.
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Perhaps addition of other cognitive domains would have provided significant detection of
differences between SMI and nSMI groups beyond what was currently found.
Future directions and recommendations
The current research provides a baseline for future researchers to utilize the cognitive
measure of story memory in conjunction with tau level differences in the entorhinal cortices
and hippocampi, with the aim of developing a neuropsychological profile for individuals who
may benefit from earlier intervention to slow progression of neurodegenerative decline.
Future research assessing these factors longitudinally in individuals who develop MCI or AD
may elucidate findings.
My method for defining SMI was in concordance with previous research and is a
widely accepted method for measuring subjective change (Eliassen et al., 2017; Jessen et al.,
2010; Vogel et al., 2017); however, it is possible the question used was not specific or
sensitive enough, and future research could include a more in-depth measure of subjective
memory complaint. A robust subjective measure may more precisely classify participants in
future research and may provide a more homogenous sample of individuals with changes in
memory which are undetectable by neuropsychological assessments alone. Furthermore,
inclusion of collateral information regarding memory change in conjunction with participant
report would likely provide a stricter SMI sample for future studies.
It would also be beneficial to employ retrospective research with participants who
were CN at baseline testing, but later went on to develop AD. This would allow for the
application of a known groups methodology and would allow for more directly relatable
results to be discussed (e.g. Jones, Livner, & Bäckman, 2006.). Specifically, as it cannot be
known if the current participants will go on to develop MCI or AD, retrospective research
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utilizing data of individuals who were shown to have developed MCI or AD would allow for
a sample specific to individuals who only displayed SMI prior to cognitive
neurodegeneration. As well, re-running the current hypotheses in a different population, such
as individuals with MCI, could provide added support for the connection between story
memory and level of tau in the left and right entorhinal cortices and hippocampi regions.
Moreover, research in a sample of individuals with MCI may further elucidate the
relationship between tau and other neuropsychological domains. Research with participants
currently diagnosed with MCI or AD would offer further support for use of SMI and
biomarker AV-1451 as a link for neurodegenerative disorders and may provide support for
level of tau binding and/or SMI presence to warrant implementation of intervention
techniques to slow progression of neurodegeneration.
The current research provides support for utilization of the Wechsler Memory ScaleIV Logical Memory I and II subtests in regard to sensitivity for level of tau in the entorhinal
cortices and hippocampi. Expanding testing of tau binding in additional neuroanatomic
regions could allow for the relationship between SMI, cognitive functioning, and tau in other
brain regions to be elucidated. As supported by research, such as that of Bäckman et al.
(2005) and Chen et al. (2001), region-specific changes in functioning other than for memory
have been seen in pre-clinical AD participants. Thus, continued research assessing these
variations and how they may relate to SMI and memory is needed and further supported by
the current research.
Lastly, a larger sample overall would increase the power of the analyses and allow for
detection of likely more nuanced differences. In addition, further equality in number of
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participants between SMI and nSMI may positively influence the ability of the statistical
analyses to detect more subtle differences within cognitively normal groups.
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